US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Maze Therapeutics (MAZE): Upsized IPO Slumps in the Aftermarket

Maze Therapeutics (MAZE) Six Month Summary: A Volatile Debut with High-Stakes Catalysts Ahead

Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO.

Maze Therapeutics Inc. (MAZE): Kidney Biotech with Blockbuster Potential Sets Terms for IPO

Legend Biotech Surges Amid Takeover Speculation—What’s Next for CARVYKTI?

IPOs and Secondary Offerings

Equity Capital Markets

Maze Therapeutics / Equity Capital Markets

<ul>
<li>The company is performing an abbreviated four-day roadshow and has gained momentum with interest from sector-dedicated investors. </li>
<li>According to our sources, the deal was considered oversubscribed at launch from a mix of new and existing investors.</li>
<li>Typically, the biotech IPOs that are eager to come out of the gates in January have fared overwhelmingly better than those that trickle out later in the year.</li>
</ul>


The company is performing an abbreviated four-day roadshow and has gained momentum with interest from sector-dedicated investors. 
According to our sources, the deal was considered oversubscribed at launch from a mix of new and existing investors.
Typically, the biotech IPOs that are eager to come out of the gates in January have fared overwhelmingly better than those that trickle out later in the year.


Maze Therapeutics Inc. (MAZE): Kidney Disease Biotech IPO Garnering Attention from Sector Investors